In this article, we cover the most important medications you need to know for osteoporosis, including bisphosphonates, selective estrogen receptor modulators, and a hypocalcemic agent. We'll start with some background on osteoporosis, including its pathophysiology.
The Nursing Pharmacology video series follows along with our Pharmacology Flashcards, which are intended to help RN and PN nursing students study for nursing school exams, including the ATI, HESI, and NCLEX.
When you see this Cool Chicken, that indicates one of Cathy's silly mnemonics to help you remember. The Cool Chicken hints in these articles are just a taste of what's available across our Level Up RN Flashcards for nursing students!
Pharmacology - Nursing Flashcards
Osteoporosis
Osteoporosis is a metabolic bone disorder that causes a lack of bone mass, leading to fragile bones and an increased risk of fractures.
If you'd like to learn more about osteoporosis, check out our Medical-Surgical flashcards for nursing students — osteoporosis is one of the musculoskeletal disorders covered, along with its pathophysiology, risk factors, signs/symptoms, diagnostics, treatment, and patient teaching; as well as an A&P refresher on bones in general.
Our bones have a process to maintain homeostasis called bone remodeling, and it involves bone cells called osteoblasts and osteoclasts.
Osteoblasts vs. osteoclasts
Osteoblasts build bones, while osteoclasts break down bones.
Osteoporosis happens when the rate of bone resorption (breakdown) by osteoclasts exceeds the rate of bone formation by osteoblasts.
Postmenopausal osteoporosis
Postmenopausal osteoporosis is the most common type of osteoporosis. Estrogen helps to stimulate bone growth and reduce the activity of osteoclasts, but a patient's estrogen levels drop precipitously when they hit menopause.
Bisphosphonates - Alendronate (Fosamax)
Alendronate (Fosamax) is a bisphosphonate that can be used for postmenopausal osteoporosis as well as Paget's disease of the bone,* which is a metabolic disorder that causes bones to be soft, structurally disorganized, and weak.
*There are at least 4 different Paget's diseases named after a 19th century doctor James Paget. In this video, Cathy says that Paget's disease is "a rare form of breast cancer," which is technically also true—but Alendronate, because it is an osteoclast inhibitor for bones, is used for Paget's disease of the bone, NOT Paget's disease of the breast. Whoops!
Mode of action
The mode of action of alendronate, along with other medications in the bisphosphonate class, is to prevent bone resorption by inhibiting the activity of osteoclasts. Remember that osteoclasts break down bones and take calcium from the bone into the bloodstream, and in the case of osteoporosis, osteoclasts are too active. Inhibiting osteoclasts helps to prevent further bone breakdown.
Side effects
Alendronate's most important side effect to be aware of is esophagitis: inflammation of the esophagus which can cause pain, difficulty swallowing, and chest pain. Other side effects include GI upset, muscle pain, and visual disturbances.
Alen drones on and on about his esophagitis.
Why can alendronate cause esophagitis?
The actual pill of Alendronate (and other bisphosphonate medications) can act as a local irritant to the gastrointestinal tract. It is hypothesized that bisphosphonates compromise the mucosal barrier, which can allow gastric acid through the epithelial lining, causing pain or a burning sensation. The patient teaching tips that follow help reduce the risk of esophagitis.
Patient teaching
Key patient teaching points for alendronate include the following.
- Patients should take alendronate on an empty stomach in the morning with a full glass of water.
- After taking alendronate, patients should sit upright or ambulate for at least 30 minutes to prevent esophageal ulceration—no lying down!
- Patients should increase their intake of calcium and vitamin D. Vitamin D is required for calcium absorption.
- Patients should engage in weight-bearing exercises to help preserve their bone mass.
- Patients' bone density should be monitored closely during therapy.
Selective estrogen receptor modulator - Raloxifene (Evista)
Raloxifene (Evista) is a selective estrogen receptor modulator used for postmenopausal osteoporosis. Raloxifene can also help reduce the risk for breast cancer.
Raloxifene helps “fix” osteoporosis (fix is spelled backwards).
Mode of action
Raloxifene's mode of action is to bind to estrogen receptors, which decreases bone resorption.
A selective receptor modulator is a drug that has different effects in different tissues. Raloxifene is unique because when it binds to estrogen receptors, it can reproduce the beneficial effects of estrogen in the bones (promoting bone growth and bone density maintenance) without the negative effects of estrogen on breast or endometrial tissue.
Another medication in this class is tamoxifen, used for breast cancer.
Side effects
Side effects of raloxifene include an increased risk of embolic events (blood clots), like a pulmonary embolism, deep vein thrombosis, or stroke. Raloxifene can also cause hot flashes or leg cramps.
Black box warning
Raloxifene carries a black box warning due to its risk of causing blood clots.
Patient teaching
If you have a patient taking raloxifene, encourage them to increase their intake of calcium and vitamin D, and to do weight-bearing exercises.
Nursing care
If you have a patient taking raloxifene, remember to monitor their bone density.
Hypocalcemic agent - Calcitonin (Miacalcin)
Calcitonin is a naturally-occurring hormone secreted by the thyroid that decreases blood calcium levels. The manufactured form of calcitonin (Miacalcin) is a hypocalcemic agent used for postmenopausal osteoporosis, as well as hypercalcemia.
Hypercalcemia is seen in hyperparathyroidism, which is a disorder of the parathyroid glands resulting in hypersecretion, or excess secretion, of parathyroid hormone (PTH) resulting in excess blood calcium levels. Hyperparathyroidism is one of the important disorders covered in our Medical-Surgical flashcards.
Tonin = Tone it down! (i.e. lowers calcium levels in the blood).
Mode of action
Calcitonin's mode of action is to prevent bone resorption by inhibiting the activity of osteoclasts. Remember that osteoclasts' primary job is to break down bone, so to retain bone density, we want to inhibit those osteoclasts. Calcitonin also increases renal excretion of calcium.
Side effects
Side effects of calcitonin include GI upset, which is very common, and if administered intranasally, nasal irritation or dryness.
Patient teaching
The patient teaching tips you need to remember with calcitonin are the same tips with the other osteoporosis medications we've covered here.
- Patients should be getting adequate calcium and vitamin D in their diet or through supplements.
- Patients should do weight bearing exercises.
If you have a patient taking calcitonin, it is important to monitor their bone density.